Dermapharm Holding SE Asset Resilience Ratio
Dermapharm Holding SE asset resilience ratio. Dermapharm Holding SE (DMP) has an Asset Resilience Ratio of 1.23% as of March 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Dermapharm Holding SE total liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Dermapharm Holding SE (2013–2025)
Asset resilience ratio of Dermapharm Holding SE from 2013 to 2025. This chart shows how Dermapharm Holding SE's Asset Resilience Ratio has changed over time. See DMP free cash flow generation to measure how efficiently the company converts operating cash flow to free cash.
Liquid Assets Composition Over Time
This chart breaks down Dermapharm Holding SE's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see balance sheet size of Dermapharm Holding SE.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | €0.00 | 0% |
| Short-term Investments | €28.06 Million | 1.23% |
| Total Liquid Assets | €28.06 Million | 1.23% |
Asset Resilience Insights
- Limited Liquidity: Dermapharm Holding SE maintains only 1.23% of assets in liquid form.
- This low level may indicate efficient asset utilization but could pose risks during economic downturns.
- The company has significant short-term investments, indicating active treasury management.
Dermapharm Holding SE Industry Peers by Asset Resilience Ratio
Compare Dermapharm Holding SE's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Takeda Pharmaceutical Company Limited
F:TKDA |
Drug Manufacturers - Specialty & Generic | 0.69% |
|
Galderma Group N
SW:GALD |
Drug Manufacturers - Specialty & Generic | 3.56% |
|
Enzymatica publ AB
ST:ENZY |
Drug Manufacturers - Specialty & Generic | 22.17% |
|
Shijiazhuang Yiling Pharmaceutical Co Ltd
SHE:002603 |
Drug Manufacturers - Specialty & Generic | 9.04% |
|
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566 |
Drug Manufacturers - Specialty & Generic | 47.16% |
|
Kangmei Pharmaceutical Co Ltd
SHG:600518 |
Drug Manufacturers - Specialty & Generic | 0.00% |
|
Walvax BioTech
SHE:300142 |
Drug Manufacturers - Specialty & Generic | 2.20% |
|
Shandong Buchang Pharmaceuticals Co Ltd
SHG:603858 |
Drug Manufacturers - Specialty & Generic | 3.47% |
Dermapharm Holding SE Asset Resilience Ratio by Year (2013–2025)
Dermapharm Holding SE asset resilience ratio by year from 2013 to 2025. The table below shows the annual Asset Resilience Ratio data for Dermapharm Holding SE.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 0.03% | €735.00K ≈ $859.29K |
€2.20 Billion ≈ $2.58 Billion |
+0.01pp |
| 2024-12-31 | 0.02% | €511.00K ≈ $597.41K |
€2.08 Billion ≈ $2.43 Billion |
-7.36pp |
| 2023-12-31 | 7.38% | €159.50 Million ≈ $186.47 Million |
€2.16 Billion ≈ $2.53 Billion |
-4.11pp |
| 2022-12-31 | 11.50% | €162.43 Million ≈ $189.89 Million |
€1.41 Billion ≈ $1.65 Billion |
-0.81pp |
| 2021-12-31 | 12.30% | €173.12 Million ≈ $202.40 Million |
€1.41 Billion ≈ $1.64 Billion |
+2.40pp |
| 2020-12-31 | 9.91% | €121.30 Million ≈ $141.81 Million |
€1.22 Billion ≈ $1.43 Billion |
-1.17pp |
| 2019-12-31 | 11.08% | €115.77 Million ≈ $135.34 Million |
€1.04 Billion ≈ $1.22 Billion |
-19.23pp |
| 2018-12-31 | 30.31% | €213.57 Million ≈ $249.69 Million |
€704.58 Million ≈ $823.73 Million |
+28.71pp |
| 2017-12-31 | 1.60% | €6.64 Million ≈ $7.76 Million |
€415.30 Million ≈ $485.53 Million |
+0.36pp |
| 2016-12-31 | 1.23% | €3.85 Million ≈ $4.50 Million |
€311.70 Million ≈ $364.41 Million |
+1.22pp |
| 2015-12-31 | 0.01% | €29.00K ≈ $33.90K |
€296.67 Million ≈ $346.83 Million |
-0.03pp |
| 2014-12-31 | 0.04% | €120.00K ≈ $140.29K |
€330.60 Million ≈ $386.50 Million |
+0.00pp |
| 2013-12-31 | 0.03% | €120.00K ≈ $140.29K |
€349.98 Million ≈ $409.16 Million |
-- |
About Dermapharm Holding SE
Dermapharm Holding SE, together with its subsidiaries, manufactures and sells off-patent branded pharmaceutical products in Germany, Italy, France, Austria, Switzerland, Spain, Portugal, the Netherlands, Croatia, Poland, Ukraine, the United States, and China. The company operates through three segments: Branded Pharmaceuticals; Other Healthcare Products; and Parallel Import Business. It offers br… Read more